about
A Review of Nebivolol Pharmacology and Clinical EvidenceGSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].PKA catalytic subunit compartmentation regulates contractile and hypertrophic responses to β-adrenergic signalingComputational models reduce complexity and accelerate insight into cardiac signaling networksPathway analysis of dilated cardiomyopathy using global proteomic profiling and enrichment maps.High sugar intake exacerbates cardiac reperfusion injury in perinatal taurine depleted adult rats.Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.Targeting GSK-3 family members in the heart: a very sharp double-edged sword.Bucindolol: a pharmacogenomic perspective on its use in chronic heart failureBeta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survivalSystems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy.Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approachSafety of perioperative β-blocker use: how do β-blockers compare in terms of side effects?Narrative review: the management of acute decompensated heart failure.Redox-sensitive mechanisms underlying vascular dysfunction in heart failure.A simple discharge risk model for predicting 1-year mortality in hospitalised acute decompansated heart failure patients with reduced ejection fraction.Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.Effects of bisoprolol in combination with trimetazidine on the treatment of heart failure and concomitant chronic obstructive pulmonary diseaseSudden cardiac death and pump failure death prediction in chronic heart failure by combining ECG and clinical markers in an integrated risk model.Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT.β-blocker therapy after acute myocardial infarction.Outpatient management of chronic heart failure.Risk score model for predicting mortality in advanced heart failure patients followed in a heart failure clinic.Therapeutic Potential of Polyphenols in Cardiac Fibrosis.Proarrhythmic Remodeling of Calcium Homeostasis in Cardiac Disease; Implications for Diabetes and Obesity
P2860
Q26801287-18749A35-49CA-48B1-9479-5E6068ED672EQ28590516-AADB3E13-85DC-43A4-8EC3-007D6A4D7B79Q30313892-3820679C-D56F-4D35-BFC4-0484C33B5769Q30408840-F80D1E9F-56A1-4E9F-A79D-74A4261DDBAFQ30428985-882AF77B-77B5-43F9-A88D-CA3AC5F2A967Q33887660-7514ABE3-581E-4210-9214-D4F404FD9072Q34364280-420BDC9B-BFCA-4CE3-AF97-E9A38950288DQ34531894-20EC068B-DD8B-41A1-B994-61C36D3F46A9Q34785999-0C54C82A-9FB6-45DB-A546-45A08ED25EC0Q35117742-1F6AD865-9B38-4CA5-91E3-AB38DB7541C5Q35640094-1BACC277-618C-488B-AA71-6C66E5E708F9Q36868077-96C080D2-9145-4D07-9D10-4934BB848B86Q37285574-68EADB56-5923-4387-8E92-25BC715FC8D0Q37830055-E1F3B48D-8DC7-4F28-B678-C48A7FDD3395Q37880500-55231CE2-5747-46B1-9440-F19398EA35E1Q38383375-AA501CA3-49F0-4DAD-BE84-BD3D55445382Q38635095-3B9B926D-7691-412D-B6EC-7F0C7A908E7CQ38750495-E560FA52-5463-4F4B-97D6-336A819BF033Q38978490-288D4801-CAB9-4E0B-9658-BD7B8B563DE0Q42371047-AEAD9CFA-2788-4770-BC77-BDE8E97AF164Q42650883-69B4F413-FDC4-43A2-A0BB-0AE15EE347F5Q43077613-5DBD3A92-91EF-4579-9C70-45ECCAA87587Q46894869-06FB98CB-E906-49C7-AC23-3974B48B22E0Q50998627-4862D624-D7DD-4321-B6B7-0258902CDE55Q51321567-B2E0BF58-E534-48C2-8E7D-2F5F484C1B92Q55289622-34BE3BC3-4C44-4F52-89B6-3EDE1B49FB91Q58693859-C5655CD4-C834-48B3-8C1E-FDB0D7049F81
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Beta-blocker use for the stages of heart failure.
@en
Beta-blocker use for the stages of heart failure.
@nl
type
label
Beta-blocker use for the stages of heart failure.
@en
Beta-blocker use for the stages of heart failure.
@nl
prefLabel
Beta-blocker use for the stages of heart failure.
@en
Beta-blocker use for the stages of heart failure.
@nl
P2860
P356
P1476
Beta-blocker use for the stages of heart failure.
@en
P2093
Marc Klapholz
P2860
P304
P356
10.4065/84.8.718
P407
P577
2009-08-01T00:00:00Z